Research advances in molecular subgroups and risk stratifications of medulloblastoma

References:

1 Massimino M,Biassoni V,Gandola L,et al.Childhood medulloblastoma[J].Crit Rev Oncol Hematol,2016,105:35-51.DOI:10.1016/j.critrevonc.2016.05.012.
2 Louis DN,Perry A,Reifenberger G,et al.The 2016 World Health Organization Classification of Tumors of the Central Nervous System:a summary[J].Acta Neuropathol,2016,131(6):803-820.DOI:10.1007/s00401-016-1545-1.
3 Millard NE,De Braganca KC.Medulloblastoma[J].J Child Neurol,2016,31(12):1341-1353.DOI:10.1177/0883073815600866.
4 Ramaswamy V,Remke M,Adamski J,et al.Medulloblastoma subgroup-specific outcomes in irradiated children:who are the true high-risk patients?[J].Neuro Oncol,2016,18(2):291-297.DOI:10.1093/neuonc/nou357.
5 Miranda Kuzan-Fischer C,Juraschka K,Taylor MD.Medulloblastoma in the molecular era[J].J Korean Neurosurg Soc,2018,61(3):292-301.DOI:10.3340/jkns.2018.0028.
6 Sabel M,Fleischhack G,Tippelt S,et al.Relapse patterns and outcome after relapse in standard risk medulloblastoma:a report from the HIT-SIOP-PNET4 study[J].J Neurooncol,2016,129(3):515-524.DOI:10.1007/s11060-016-2202-1.
7 Skowron P,Ramaswamy V,Taylor MD.Genetic and molecular alterations across medulloblastoma subgroups[J].J Mol Med,2015,93(10):1075-1084.DOI:10.1007/s00109-015-1333-8.
8 Northcott PA,Korshunov A,Witt H,et al.Medulloblastoma comprises four distinct molecular variants[J].J Clin Oncol,2011,29(11):1408-1414.DOI:10.1200/JCO.2009.27.4324.
9 Northcott PA,Robinson GW,Kratz CP,et al.Medulloblastoma[J].Nat Rev Dis Primers,2019,5(1):11.DOI:10.1038/s41572-019-0063-6.
10 Schwalbe EC,Williamson D,Lindsey JC,et al.DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies[J].Acta Neuropathol,2013,125(3):359-371.DOI:10.1007/s00401-012-1077-2.
11 Hovestadt V,Remke M,Kool M,et al.Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays[J].Acta Neuropathol,2013,125(6):913-916.DOI:10.1007/s00401-013-1126-5.
12 Cavalli FMG,Remke M,Rampasek L,et al.Intertumoral heterogeneity within medulloblastoma subgroups[J].Cancer Cell,2017,31(6):737-754.DOI:10.1016/j.ccell.2017.05.005.
13 Schwalbe EC,Lindsey JC,Nakjang S,et al.Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma:a cohort study[J].Lancet Oncol,2017,18(7):958-971.DOI:10.1016/S1470-2045(17)30243-7.
14 Gibson P,Tong Y,Robinson G,et al.Subtypes of medulloblastoma have distinct developmental origins[J].Nature,2010,468(7327):1095-1099.DOI:10.1038/nature09587.
15 Taylor MD,Northcott PA,Korshunov A,et al.Molecular subgroups of medulloblastoma:the current consensus[J].Acta Neuropathol,2012,123(4):465-472.DOI:10.1007/s00401-011-0922-z.
16 Kool M,Korshunov A,Remke M,et al.Molecular subgroups of medulloblastoma:an international meta-analysis of transcriptome,genetic aberrations,and clinical data of WNT,SHH,Group 3,and Group 4 medulloblastomas[J].Acta Neuropathol,2012,123(4):473-484.DOI:10.1007/s00401-012-0958-8.
17 Phoenix TN,Patmore DM,Boop S,et al.Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype[J].Cancer Cell,2016,29(4):508-522.DOI:10.1016/j.ccell.2016.03.002.
18 Duchartre Y,Kim YM,Kahn M.The Wnt signaling pathway in cancer[J].Crit Rev Oncol Hematol,2016,99:141-149.DOI:10.1016/j.critrevonc.2015.12.005.
19 Waszak SM,Northcott PA,Buchhalter I,et al.Spectrum and prevalence of genetic predisposition in medulloblastoma:a retrospective genetic study and prospective validation in a clinical trial cohort[J].Lancet Oncol,2018,19(6):785-798.DOI:10.1016/S1470-2045(18)30242-0.
20 Villani A,Malkin D,Tabori U.Syndromes predisposing to pediatric central nervous system tumors:lessons learned and new promises[J].Curr Neurol Neurosci Rep,2012,12(2):153-164.DOI:10.1007/s11910-011-0244-5.
21 Qualman SJ,Bowen J,Erdman SH,et al.Molecular basis of the brain tumor-polyposis (Turcot) syndrome[J].Pediatr Dev Pathol,2003,6(6):574-576.DOI:10.1007/s10024-003-7068-5.
22 Clifford SC,Lusher ME,Lindsey JC,et al.Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis[J].Cell Cycle,2006,5(22):2666-2670.DOI:10.4161/cc.5.22.3446.
23 Northcott PA,Buchhalter I,Morrissy AS,et al.The whole-genome landscape of medulloblastoma subtypes[J].Nature,2017,547(7663):311-317.DOI:10.1038/nature22973.
24 Wang J,Garancher A,Ramaswamy V,et al.Medulloblastoma:from molecular subgroups to molecular targeted therapies[J].Annu Rev Neurosci,2018,41:207-232.DOI:10.1146/annurev-neuro-070815-013838.
25 Archer TC,Weeraratne SD,Pomeroy SL.Hedgehog-GLI pathway in medulloblastoma[J].J Clin Oncol,2012,30(17):2154-2156.DOI:10.1200/JCO.2011.41.1181.
26 Carballo GB,Honorato JR,de Lopes GPF,et al.A highlight on Sonic hedgehog pathway[J].Cell Commun Signal,2018,16(1):11.DOI:10.1186/s12964-018-0220-7.
27 Zhukova N,Ramaswamy V,Remke M,et al.Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma[J].J Clin Oncol,2013,31(23):2927-2935.DOI:10.1200/JCO.2012.48.5052.
28 Remke M,Ramaswamy V,Peacock J,et al.TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma[J].Acta Neuropathol,2013,126(6):917-929.DOI:10.1007/s00401-013-1198-2.
29 Kool M,Jones DT,J?ger N,et al.Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition[J].Cancer Cell,2014,25(3):393-405.DOI:10.1016/j.ccr.2014.02.004.
30 Northcott PA,Rutka JT,Taylor MD.Genomics of medulloblastoma:from Giemsa-banding to next-generation sequencing in 20 years[J].Neurosurg Focus,2010,28(1):E6.DOI:10.3171/2009.10.FOCUS09218.
31 Robinson GW,Rudneva VA,Buchhalter I,et al.Risk-adapted therapy for young children with medulloblastoma (SJYC07):therapeutic and molecular outcomes from a multicentre,phase 2 trial[J].Lancet Oncol,2018,19(6):768-784.DOI:10.1016/S1470-2045(18)30204-3.
32 Raybaud C,Ramaswamy V,Taylor MD,et al.Posterior fossa tumors in children:developmental anatomy and diagnostic imaging[J].Childs Nerv Syst,2015,31(10):1661-1676.DOI:10.1007/s00381-015-2834-z.
33 Kawauchi D,Robinson G,Uziel T,et al.A mouse model of the most aggressive subgroup of human medulloblastoma[J].Cancer Cell,2012,21(2):168-180.DOI:10.1016/j.ccr.2011.12.023.
34 Tseng YY,Moriarity BS,Gong W,et al.PVT1 dependence in cancer with MYC copy-number increase[J].Nature,2014,512(7512):82-86.DOI:10.1038/nature13311.
35 Northcott PA,Shih DJ,Peacock J,et al.Subgroup-specific structural variation across 1,000 medulloblastoma genomes[J].Nature,2012,488(7409):49-56.DOI:10.1038/nature11327.
36 Northcott PA,Lee C,Zichner T,et al.Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma[J].Nature,2014,511(7510):428-434.DOI:10.1038/nature13379.
37 Northcott PA,Jones DT,Kool M,et al.Medulloblastomics:the end of the beginning[J].Nat Rev Cancer,2012,12(12):818-834.DOI:10.1038/nrc3410.
38 Shih DJ,Northcott PA,Remke M,et al.Cytogenetic prognostication within medulloblastoma subgroups[J].J Clin Oncol,2014,32(9):886-896.DOI:10.1200/JCO.2013.50.9539.
39 Kunder R,Jalali R,Sridhar E,et al.Real-time PCR assay based on the differential expression of microRNAs and protein-coding genes for molecular classification of formalin-fixed paraffin embedded medulloblastomas[J].Neuro-oncology,2013,15(12):1644-1651.DOI:10.1093/neu-onc/not123.
40 Lin CY,Erkek S,Tong Y,et al.Active medulloblastoma enhancers reveal subgroup-specific cellular origins[J].Nature,2016,530(7588):57-62.DOI:10.1038/nature16546.
41 Remke M,Hielscher T,Korshunov A,et al.FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma[J].J Clin Oncol,2011,29(29):3852-3861.DOI:10.1200/JCO.2011.36.2798.
42 孙晓非,甄子俊.儿童髓母细胞瘤多学科诊疗专家共识(CCCG-MB-2017)[J].中国小儿血液与肿瘤杂志,2018,23(4):169-174.DOI:10.3969/j.issn.1673-5323.2018.04.001. Sun XF,Zhen ZJ.Multidisciplinary expert consensus on the diagnosis and treatment of childhood medulloblastoma (CCCG-MB-2017)[J].J China Pediatr Blood Cancer,2018,23(4):169-174.DOI:10.3969/j.issn.1673-5323.2018.04.001.
43 Ramaswamy V,Remke M,Bouffet E,et al.Risk stratification of childhood medulloblastoma in the molecular era:the current consensus[J].Acta Neuropathol,2016,131(6):821-831.DOI:10.1007/s00401-016-1569-6.